CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+27.21%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.15B
AUM Growth
+$1.15B
(+34%)
Cap. Flow
+$129M
Cap. Flow
% of AUM
11.2%
Top 10 Holdings %
Top 10 Hldgs %
65.7%
Holding
58
New
9
Increased
8
Reduced
26
Closed
9
Top Buys
| 1 |
Nektar Therapeutics
NKTR
|
$60.1M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$38.6M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
$28.5M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$21.1M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
$20M |
Top Sells
| 1 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
$25.1M |
| 2 |
KA
Kineta, Inc. Common Stock
KA
|
$19.2M |
| 3 |
AnaptysBio
ANAB
|
$15.3M |
| 4 |
BLUE
bluebird bio
BLUE
|
$14.2M |
| 5 |
Wave Life Sciences
WVE
|
$7.09M |
Sector Composition
| 1 | Healthcare | 96.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Nektar Therapeutics
NKTR
$568M
| $272M | 20.3% | 2,563,200 +565,500 | +28% | +$60.1M |
|
|
2
AnaptysBio
ANAB
$569M
| $115M | 8.57% | 1,104,022 -147,463 | -12% | -$15.3M |
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $90.4M | 6.74% | 4,088,229 +319,472 | +8% | +$7.06M |
|
|
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $58.9M | 4.39% | 1,918,350 +686,828 | +56% | +$21.1M |
|
5
InflaRx
IFRX
$108M
| $40.3M | 3.01% | 1,399,030 -39,177 | -3% | -$1.13M |
|
|
BPMC
6
DELISTED
Blueprint Medicines
BPMC
| $39.6M | 2.95% | 432,063 -17,937 | -4% | -$1.64M |
|
|
SAGE
7
DELISTED
Sage Therapeutics
SAGE
| $38.6M | 2.88% | +239,619 | New | +$38.6M |
|
|
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $37.4M | 2.79% | 767,363 -32,637 | -4% | -$1.59M |
|
|
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $34.4M | 2.57% | 3,600,954 -55,715 | -2% | -$533K |
|
10
Theravance Biopharma
TBPH
$699M
| $31.5M | 2.35% | 1,300,000 +400,000 | +44% | +$9.7M |
|
|
11
Rocket Pharmaceuticals
RCKT
$354M
| $28.5M | 2.12% | +1,519,891 | New | +$28.5M |
|
|
GTHX
12
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $26.7M | 1.99% | 719,985 -177,520 | -20% | -$6.58M |
|
13
Ascendis Pharma
ASND
$11.8B
| $24.3M | 1.81% | 371,739 +71,739 | +24% | +$4.69M |
|
|
AVXS
14
DELISTED
AveXis, Inc. Common Stock
AVXS
| $23.7M | 1.77% | 192,094 -7,906 | -4% | -$977K |
|
15
argenx
ARGX
$43.6B
| $22.4M | 1.67% | 278,536 -11,464 | -4% | -$922K |
|
|
QTNT
16
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $20.2M | 1.51% | 4,290,852 -197,269 | -4% | -$929K |
|
17
Clearside Biomedical
CLSD
$28.9M
| $20.2M | 1.5% | 1,880,880 -60,000 | -3% | -$644K |
|
|
TSRO
18
DELISTED
TESARO, Inc.
TSRO
| $20M | 1.49% | +350,000 | New | +$20M |
|
19
Vanda Pharmaceuticals
VNDA
$279M
| $16.1M | 1.2% | +957,821 | New | +$16.1M |
|
20
Neurocrine Biosciences
NBIX
$13.8B
| $15.8M | 1.18% | 191,112 -8,888 | -4% | -$737K |
|
21
Omeros
OMER
$283M
| $14.7M | 1.09% | 1,314,118 +439,118 | +50% | +$4.91M |
|
22
Quanterix
QTRX
$211M
| $14.4M | 1.08% | 847,789 | – | – |
|
23
VYNE Therapeutics
VYNE
$8.16M
| $12.7M | 0.94% | +336,714 | New | +$12.7M |
|
|
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
| $10.9M | 0.81% | 668,743 -31,257 | -4% | -$510K |
|
|
BOLD
25
DELISTED
Audentes Therapeutics, Inc
BOLD
| $9.7M | 0.72% | 322,945 -14,931 | -4% | -$449K |
|